STAT+: Obesity drug Wegovy gets FDA approval to add cardiovascular benefits on its label
STAT
MARCH 8, 2024
regulators approved a label expansion for Novo Nordisk’s obesity drug Wegovy to tout its benefits for the heart, a move that could boost demand and insurance coverage for the already highly popular treatment. Novo said it has also filed for a label expansion in Europe and a decision is expected this year.
Let's personalize your content